GlobalData on MSN4mon
EASD 2024: Innovent shows off mazdutide’s efficacy in diabetes and obesity
Innovent Biologics has released more data from two Phase III trials evaluating mazdutide in adults with type 2 diabetes and ...
Hosted on MSN7mon
Innovent’s Obesity Drug Shows Similar Weight Loss as Eli Lilly’s
Patients who took the higher dose of Innovent’s mazdutide for 48 weeks lost nearly 15% of their body weight in a study of more than 610 Chinese people who were either overweight or obese ...
pharmaphorum5d
Innovent throws its hat further into China's GLP-1 ring
Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly.